[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SciNeuro\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":39},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100608301",false,"NCT07199777","A Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in DME Patients","A Phase 2a, Randomized, Double-masked, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of SNP318 in Patients With Diabetic Macular Edema","Main Inclusion Criteria:\n\n1. Confirmed diabetes mellitus Type 1 or Type 2, with stable glycemic control\n2. Center-involved DME with CST \\>=320 µm (Study eye)\n3. BCVA between 82 and 25 letters, inclusive (Study eye)\n4. BCVA score ≥ 25 letters (Non-study eye)\n\nMain Exclusion Criteria:\n\n1\\. Use of the last intravitreal anti-VEGF injection in the study eye within 90 days prior to Screening","ALL","18 Years",{"count":18,"type":19},60,"ESTIMATED","INTERVENTIONAL",[22],"PHASE2","The objective of this study is to assess the safety, efficacy, and tolerability of SNP318 in patients with DME.",[25,26],"Diabetic Macular Edema","DME","NOT_YET_RECRUITING","2025-09-22",{"date":30,"type":31},"2025-09-30","ACTUAL",{"date":33,"type":19},"2025-11",{"date":35,"type":19},"2027-03",{"name":37,"class":38},"SciNeuro","INDUSTRY",""]